pharma · Obesity · Type 2 diabetes
NovoThirteen
NovoThirteen clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Bagsværd, JP
- Programs
- 94
- Drugs
- 67
- Patents
- 0
NovoThirteen projects
13 ClinicalTrials.gov programs sponsored by NovoThirteen.
NovoThirteen has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
NN6019-7565
NovoThirteen
Participants with transthyretin amyloid cardiomyopathy (ATTR CM)
1 trial -
NN6706-8212
NovoThirteen
Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.
1 trial -
NN6706-8282
NovoThirteen
Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.
1 trial -
NN7533-4470
NovoThirteen
Sickle cell disease
1 trial -
NN8640-4245
NovoThirteen
SGA - small for gestational age children
1 trial -
NN9388-7700
NovoThirteen
Chronic Kidney Disease, Type 2 diabetes
1 trial -
NN9388-7864
NovoThirteen
Type 2 diabetes and painful diabetic peripheral neuropathy
1 trial -
NN9490-7678
NovoThirteen
Type 2 Diabetes
1 trial -
NN9500-4656
NovoThirteen
Non-alcoholic steatohepatitis (NASH)
1 trial -
NN9500-7730
NovoThirteen
alcohol-related liver disease
1 trial -
NN9541-7841
NovoThirteen
Chronic Kidney Disease, with or without Type 2 diabetes, Obesity
1 trial -
NN9662-8160
NovoThirteen
type 2 diabetes
1 trial -
etavopivat B 10041, etavopivat B 10042
NovoThirteen
Sickle Cell Disease
1 trial
Frequently asked questions
How many clinical projects does NovoThirteen have?
13 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.